Vasopressin as an adjunct therapy for pulmonary hypertension: A case report

Andra Malikiwi, Arun Sasi, Kenneth Hark Hong Tan, Arvind Sehgal

Research output: Contribution to journalArticleOtherpeer-review

Abstract

UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.

CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.

Original languageEnglish
Pages (from-to)1651-1654
Number of pages4
JournalEuropean Journal of Pediatrics
Volume173
Issue number12
DOIs
Publication statusPublished - 1 Dec 2014

Cite this

@article{82eb0ebed44b40748ab14c98d58f5605,
title = "Vasopressin as an adjunct therapy for pulmonary hypertension: A case report",
abstract = "UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.",
author = "Andra Malikiwi and Arun Sasi and Tan, {Kenneth Hark Hong} and Arvind Sehgal",
year = "2014",
month = "12",
day = "1",
doi = "10.1007/s00431-013-2225-y",
language = "English",
volume = "173",
pages = "1651--1654",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer-Verlag London Ltd.",
number = "12",

}

Vasopressin as an adjunct therapy for pulmonary hypertension : A case report. / Malikiwi, Andra; Sasi, Arun; Tan, Kenneth Hark Hong; Sehgal, Arvind.

In: European Journal of Pediatrics, Vol. 173, No. 12, 01.12.2014, p. 1651-1654.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Vasopressin as an adjunct therapy for pulmonary hypertension

T2 - A case report

AU - Malikiwi, Andra

AU - Sasi, Arun

AU - Tan, Kenneth Hark Hong

AU - Sehgal, Arvind

PY - 2014/12/1

Y1 - 2014/12/1

N2 - UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.

AB - UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.

UR - http://www.scopus.com/inward/record.url?scp=84937511538&partnerID=8YFLogxK

U2 - 10.1007/s00431-013-2225-y

DO - 10.1007/s00431-013-2225-y

M3 - Article

VL - 173

SP - 1651

EP - 1654

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 12

ER -